Long-term overall survival and progression-free survival in idiopathic pulmonary fibrosis treated by pirfenidone or nintedanib or their switch. Real world data from the EMPIRE registry

Vašáková, Martina; Šterclová, Martina; Moğulkoç, Nesrin; Lawandowska, Katerzyna; Müller, Veronika; Hájková, Marta; Jovanović, Dragana; Tekavec-Trkanjec, Jasna; Kramer, Mordechai R.; Studnicka, Michael; Stoeva, Natalia; Littnerová, Simona; Hejduk, Karel; Dušek, Ladislav

doi:10.1183/13993003.congress-2019.pa4720

Cited by 6 publications

(10 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Data from the INPULSIS trials are supported by those from the randomized, double-blind, multinational, phase III INSTAGE trial evaluating nintedanib plus sildenafil versus nintedanib alone in the treatment of patients with advanced IPF [12] and numerous real-world studies (e.g. [13][14][15][16][17][18][19][20]).…”

Section: Nintedanib: Clinical Considerations In Fibrotic Ildsmentioning

confidence: 92%

“…Real-world data on the long-term effectiveness of nintedanib in the treatment of IPF are available from a retrospective analysis of data from the European MultiPartner IPF (EMPIRE) registry, which compared nintedanib ( n = 637), pirfenidone ( n = 821), switched treatment (i.e. from nintedanib to pirfenidone or vice versa; n = 148) and other or no treatment ( n = 1139) [ 19 ]. The clinical effectiveness of nintedanib ( n = 593) and pirfenidone ( n = 662) was also evaluated in a retrospective cohort analysis using data from a US insurance database, in which patients with IPF treated with an antifibrotic drug were one-to-one propensity score matched with untreated patients [ 17 ].…”

Section: Therapeutic Efficacy Of Nintedanibmentioning

confidence: 99%

See 1 more Smart Citation

Nintedanib: A Review in Fibrotic Interstitial Lung Diseases

Lamb

2021

Drugs

View full text Add to dashboard Cite

Progressive fibrosing interstitial lung diseases (ILDs) involve similar pathophysiological processes, indicating the potential for common approaches to treatment. Nintedanib (Ofev ® ), an intracellular tyrosine kinase inhibitor (TKI) with antifibrotic properties, was one of the first drugs approved for use in idiopathic pulmonary fibrosis (IPF) and has more recently been approved for use in other chronic fibrosing ILDs with a progressive phenotype and systemic sclerosis-associated ILD (SSc-ILD). In multinational phase III trials, nintedanib significantly reduced the annual rate of decline in forced vital capacity (FVC) in adults with IPF, other progressive fibrosing ILDs and SSc-ILD. Reductions in FVC decline with nintedanib in patients with IPF and severe gas exchange impairment were comparable to those in patients with milder disease. Real-world experience in patients with IPF supports the effectiveness of nintedanib in slowing ILD progression. Nintedanib had a manageable tolerability profile in patients with fibrotic ILDs in clinical trials and real-world studies. No new safety signals have emerged from global pharmacovigilance data. Nintedanib continues to represent an important therapeutic option in patients with IPF and is the first drug to be approved for use in patients with other chronic fibrosing ILDs with a progressive phenotype or SSc-ILD, with these approvals expanding the range of fibrotic ILDs for which nintedanib can be prescribed. Plain language summaryTreatment options for fibrotic interstitial lung diseases (ILDs) that involve progressive lung function decline have historically been limited. Nintedanib (Ofev ® ) was one of the first antifibrotic drugs to be approved for use in idiopathic pulmonary fibrosis and is now also approved for use in other chronic fibrosing ILDs with a progressive phenotype and systemic sclerosisassociated ILD (SSc-ILD). Nintedanib reduced lung function deterioration in patients with idiopathic pulmonary fibrosis, other chronic fibrosing ILDs with a progressive phenotype and SSc-ILD in well-designed clinical trials. In patients with idiopathic pulmonary fibrosis, the clinical benefit of nintedanib was shown to persist over more than 4 years of treatment. The most common adverse events in nintedanib recipients were diarrhoea and nausea, which were manageable in the majority of patients. Real-world experience supports the effectiveness and acceptable safety of nintedanib. Nintedanib remains an important treatment option for patients with idiopathic pulmonary fibrosis and is the first drug to be approved for use in patients with other chronic fibrosing ILDs with a progressive phenotype and SSc-ILD.

show abstract

Section: Nintedanib: Clinical Considerations In Fibrotic Ildsmentioning

confidence: 92%

Section: Therapeutic Efficacy Of Nintedanibmentioning

confidence: 99%

Nintedanib: A Review in Fibrotic Interstitial Lung Diseases

Lamb

2021

Drugs

View full text Add to dashboard Cite

show abstract

“…In the analysed group, the prognosis was more favourable for patients treated with nintedanib and those who changed one antifibrotic drug to the other. Nevertheless, in view of the limitations of this analysis, no definitive, generalised conclusions may be drawn [25].…”

Section: Effect Of Treatment With Nintedanib On Survivalmentioning

confidence: 87%

“…The results of an analysis of pooled data from 6 clinical trials, based on which a mathematical model was developed, are also optimistic; the average improvement in survival in patients treated with nintedanib compared to the placebo group is estimated at nearly 8 years (11.6 vs 3.7), and median survival is improved by 5.2 years (8.5 vs 3.3) [24]. No less promising are the results of a retrospective analysis of the population of 2745 patients with IPF included in the international register EMPIRE (which also includes Polish patients), presented at the congress of the European Respiratory Society (ERS) in 2019 and confirming a significant increase in overall and progression-free survival in patients treated with antifibrotic drugs as compared to untreated patients [25]. In the analysed group, the prognosis was more favourable for patients treated with nintedanib and those who changed one antifibrotic drug to the other.…”

Section: Effect Of Treatment With Nintedanib On Survivalmentioning

confidence: 99%

Nintedanib—Efficacy, Safety and Practical Aspects of Treatment for Patients with Idiopathic Pulmonary Fibrosis

Martusewicz-Boros¹,

Górska

2020

Advances in Respiratory Medicine

View full text Add to dashboard Cite

Idiopathic pulmonary fibrosis (IPF) is a rare disease with progressive course and a very unfavourable prognosis. Antifibrotic drugs are a chance to reduce the rate of disease progression and extend the life of IPF patients. One of these drugs is nintedanib, an oral tyrosine kinase inhibitor. In the following article, the reader will find a summary of current knowledge on the efficacy and safety of nintedanib treatment of IPF patients. This study uses data from pivotal studies and experience from everyday clinical practice indicating a wide range of possible applications of the drug in IPF patients.

show abstract

“…Данные по выживаемости на терапии, проанализированные в самом большом европейском регистре ИЛФ EMPIRE [39], показали, что лучшая выживаемость наблюдалась в группе пациентов, где произошла смена антифибротических препаратов, а также в группе пациентов, получавших нинтеданиб (рис. 4).…”

Section: основные направления в леченииunclassified

Interstitial lung diseases with progressive pulmonary fibrosis: pathogenetic features and approaches to therapy

2020

View full text Add to dashboard Cite

A number of patients with interstitial lung diseases (ILD) of various etiologies, including hypersensitive pneumonitis, diffuse connective tissue diseases (rheumatoid arthritis, systemic scleroderma, dermatomyositis), sarcoidosis, idiopathic non-specific interstitial pneumonia (NSIP) and unclassified ILD develop rapid deterioration of lung ventilation function due to the progression of fibrotic changes, accompanied by a decrease in physical performance and quality of life. It is proposed to distinguish a progressive fibrotic phenotype from those with similar pathogenetic mechanisms, radiologic pattern, clinical course, and prognosis. The progressive course of the fibrotic process is assessed by reducing the forced vital capacity of the lungs (FVC), increasing the severity of signs of pulmonary fibrosis according to computed tomography (CT) and worsening respiratory symptoms. There are several risk factors for the progression of ILD, such as male gender, older age, lower initial pulmonary function, and radiological or pathological picture of usual interstitial pneumonia (UIP). Currently, the role of antifibrotic drugs in the treatment of this pathology is being actively studied. Previously, the common approach was to use this group of drugs in patients with idiopathic pulmonary fibrosis (IPF) and immunosuppressive drugs in patients with other fibrotic subtypes of IL. However, the results of clinical studies have shown a favorable response to antifibrotic therapy for a wider range of fibrotic ILD, manifested in a decrease in the annual rate of FVC reduction. And in 2020, the use of the first anti-fibrotic drug was approved for the treatment of patients with advanced pulmonary fibrosis, NOT related to idiopathic pulmonary fibrosis (IPF).

show abstract

Long-term overall survival and progression-free survival in idiopathic pulmonary fibrosis treated by pirfenidone or nintedanib or their switch. Real world data from the EMPIRE registry

Cited by 6 publications

References 0 publications

Nintedanib: A Review in Fibrotic Interstitial Lung Diseases

Nintedanib: A Review in Fibrotic Interstitial Lung Diseases

Nintedanib—Efficacy, Safety and Practical Aspects of Treatment for Patients with Idiopathic Pulmonary Fibrosis

Interstitial lung diseases with progressive pulmonary fibrosis: pathogenetic features and approaches to therapy

Contact Info

Product

Resources

About